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Among the second-generation photosensitizers (PS) developed for
the treatment of neoplastic diseases by photodynamic therapy
(PDT) (Kessel, 1996; Ochsner, 1997), metallo-phthalocyanines
(MePc) have been proposed (Spikes, 1986; van Lier, 1990;
Rosenthal, 1991) as an alternative to Photofrin (PII), the only PS
currently approved for clinical use. Their stronger absorption
in the red part of the spectrum (molar extinction coefficient,
2.5  ´ 105 M–1 cm–1 at 675 nm), where the depth of light penetration
in tissues is twice that obtained at 630 nm with PII (Svaasand,
1984), together with their chemical homogeneity and their lower
potential to induce cutaneous photosensitivity (Roberts et al, 1989;
Tralau et al, 1989) are major advantages over PII.
Unsubstituted MePc are not soluble in physiological solvents
and their in vivo administration relies upon their incorporation into
carriers, such as the liposomal formulation of ZnPc (Isele et al,
1995), or their chemical conversion into water-soluble dyes by the
attachment of selected substituents onto the benzene rings of the
macrocycle. An inverse relationship was related between the
degree of substitution by sulphonato groups of MePc and their
hydrophobicity and photodynamic activities, both at the cellular
level and in tumour-bearing mice (Brasseur et al, 1987, 1988;
Paquette et al, 1988; Berg et al, 1989; Chan et al, 1990, 1991;
Margaron et al, 1996a). The potential of the water-soluble
aluminium sulphophthalocyanine (AlPcS) to generate activated
oxygen species (Sharman et al, 1999) and to induce a photo-
dynamic response in vivo has been widely evaluated, and a
mixture of AlPcS bearing 2–4 sulphonato groups per Pc
(Photosense) is used extensively and successfully in clinical PDT
in Russia (Zharkova et al, 1994). Furthermore, the di-sulphonated
derivative has been shown to induce tumour regression mainly via
direct tumour cell kill rather than damage to the tumour vascula-
ture, as observed for PII (Chan et al, 1996; Margaron et al, 1996b).
The unsubstituted AlClPc has, however, attracted less attention
even though it has been shown that this compound formulated as a
Cremophor emulsion was preferentially retained by a gliosarcoma
and was able to induce tumour necrosis in this model (Dereski
et al, 1994). More recently, we demonstrated that the Cremophor-
formulated AlClPc was more effective in inducing tumour regres-
sion in EMT-6 tumour-bearing mice than the mono- through
tetrasulphonated derivatives, while exerting relatively minor
effects against normal tissues (Chan et al, 1997). The low dosage
required together with the absence of systemic toxicity, even at
much higher doses, renders the AlClPc Cremophor emulsion one
of the most potent photosensitizer preparations currently available
in terms of therapeutic window. However, Cremophor oil is known
to induce unwanted side-effects in patients (Dye and Watkins,
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Summary The potential use of unsubstituted aluminium phthalocyanine (AlClPc) as a sensitizer for photodynamic therapy (PDT) of cancer
has not been fully exploited in spite of its higher efficiency as compared to the sulphonated derivatives. This is largely due to the strong
hydrophobic character of AlClPc which renders the material difficult to formulate for in vivo administration. We prepared two water-soluble
derivatives of AlClPc by axial coordination of polyethyleneglycol (PEG, MW 2000) or polyvinylalcohol (PVA, MW 13 000–23 000) to the central
aluminium ion. Their photodynamic activities were evaluated in vitro against the EMT-6 mouse mammary tumour cells and in vivo against the
EMT-6 and the colon carcinoma Colo-26 tumours implanted intradermally in Balb/c mice. Pharmacokinetics were studied in the EMT-6
tumour-bearing mice. After 1 h incubation, the light dose required to kill 90% of cells (LD90) was at least three times less for AlClPc
(Cremophor emulsion) as compared to AlPc–PEG and AlPc–PVA, while after 24 h incubation all three preparations were highly phototoxic.
All three dye preparations induced complete EMT-6 tumour regression in 75–100% of animals at a low drug dose (0.25 mmol kg–1) following
PDT (400 J cm–2, 650–700 nm) at 24 h pi. Complete tumour regression in the Colo-26 tumour model was obtained in 30% of mice at a dose
of 2 mmol kg–1. In the non-cured animals, AlPc–PVA induced the most significant tumour growth delay. This dye showed a prolonged plasma
half-life (6.8 h) as compared to AlClPc (2.6 h) and AlPc–PEG (23 min), lower retention by liver and spleen and higher tumour-to-skin
and tumour-to-muscle ratios. Our data demonstrate that addition of hydrophilic axial ligands to AlPc, while modifying in vitro and in vivo
kinetics, does not reduce the PDT efficiency of the parent molecule. Moreover, in the case of the polyvinylalcohol derivative, axial coordination
confers advantageous pharmacokinetics to AlPc, which makes this photosensitizer a valuable, water soluble candidate drug for clinical PDT
of cancer.
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Correspondence to:: JE van Lier1980). On such account we conjectured that the coordination of a
biologically acceptable polymer on the central Al3+ ion would
confer water solubility to AlPc without changing the electronic
structure and photochemical properties, and without adding any
isomerism. By adapting the reaction of Koenigs–Knorr, it was
possible to attach a phenolic polyethyleneglycol (PEG) or a
phenolic polyvinylalcohol (PVA) via a coordination bond,
replacing the Cl substituent of AlClPc, to obtain water-soluble
AlPc–PEG and –PVA conjugates. The photodynamic activity of
these two analogues was evaluated and compared with that of the
unsubstituted AlClPc in vitro against the EMT-6 mouse mammary
tumour cell line and in vivo against the EMT-6 and the colon carci-
noma Colo-26 tumours implanted intradermally (i.d.) in Balb/c
mice. Pharmacokinetics were performed in the EMT-6 tumour-
bearing mice. In spite of differences in the biodistribution pattern
of the three dye preparations, the coordination of polymeric, axial
ligands to AlPc does not reduce its photoefficiency and results in
potent, water-soluble photosensitizer preparations.
MATERIALS AND METHODS
Chemistry
General
The UV-vis spectra were recorded with a Hitachi U-2000 spectro-
photometer. All solvents and chemicals were purchased from
Aldrich Chemical Co. (Milwaukee, WI, USA) and were used
without further purification. PEG with a MW 2000 g and an
average degree of polymerization of 43, PVA (MW 13–23 ´ 103)
and AlClPc, were obtained from Aldrich. The Bolton-Hunter
reagent was obtained from Pierce (Rockford, IL, USA).
Reaction of AlClPC with PEG-2000
In order to activate the PEG (1) to react with AlClPc, the material
was converted in a three-step reaction to a phenoxy derivative (4)
(Scheme 1). Briefly this involved substitution of the free hydroxyl
groups with chloro groups through a reaction with thionyl chloride
to yield 2, followed by a reaction with 4-benzyloxyphenol to yield
the protected benzylphenoxy-PEG derivative (3) (Casnati et al,
1997) which upon hydrolysis gives the activated phenoxy-PEG
(4). Reaction of 4 with AlClPc, silver carbonate and silver
perchlorate under Koenigs–Knorr conditions in DMF (Egan,
1972; Wulff and Röhle, 1974) afforded the axial substituted
AlPc–PEG (5) (Figure 1). The mass spectra of all PEG derivatives
failed to show any molecular ions above 2500. Evidence of the
reaction with AlClPc was ascertained by the water solubility of the
axial coordinated AlPc–PEG (5) and its characteristic UV-vis
spectrum (Figure 2). The peak at 670 nm, typical for monomeric
1534 N Brasseur et al
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Figure 1 Structural formula of AlPc–PEG (5) (x = -O-PEG) and AlPc-PVA
(10) (x = -(CH2)2CONH(CH2)3NH-PVA). See also Schemes 1 and 2
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Figure 2 UV-vis spectrum of AlPc–PEG at 1 min, 30 min, 45 min, 1 h, 16 h
and 24 h after dilution at 2.8 10–6 M in DMF. The peaks characteristic for the
monomeric dye at 604 and 670 nm increase while the peak of the aggregate
at 634 nm decreases
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Scheme 2AlPc, increases with time after dilution of 5 in DMF, suggesting
aggregation of AlPc–PEG in aqueous solution. Direct mixing of
AlClPc and PEG did not give a blue aqueous solution, confirming
that PEG alone was not able to solubilize AlClPc.
Reaction of AlClPc with PVA
The PVA was activated as a phenoxy derivative attached to
the PVA via an amine substituent (Scheme 2). Briefly, the PVA
(6) was reacted with 2-fluoro-N-methylpyridinium p-toluene-
sulphonate to activate the hydroxyl groups, i.e. compound 7
(Jiang et al, 1990), that were then attacked by the nucleophilic
1,3-diaminopropane to give the polyamino-PVA 8. An average of
ten amines per PVA was calculated after the reaction with sodium
benzenetrinitrosulphonate (Fields, 1972). Compound 8 was then
coupled via an amide linkage using the Bolton-Hunter reagent, to
yield the activated phenolic PVA (9). This phenolic polymer was
condensed with AlClPc as described for PEG above to give the
axial substituted AlPc–PVA 10 (Figure 1), which was character-
ized by its UV-vis absorption spectrum. Details of the synthetic
procedures will be published elsewhere.
The final stock solutions of the conjugates remained stable,
even after 3 months at room temperature, as evidenced by the
absence of precipitate (0.45 mm-filter) and integrity of the absorp-
tion spectrum.
Biological studies
Drug formulation
AlClPc was formulated in an oil emulsion containing 10%
Cremophor EL (Sigma) and 3% 1,2-propanediol (Sigma) in
phosphate-buffered saline (PBS). After dissolution of AlClPc in a
minimal volume of ethanol, Cremophor and 1,2-propanediol were
added under sonication, whereafter ethanol was evaporated under
vacuum. The solution was diluted with PBS pH 7.4 and filtered
(Millipore, 0.22 mm). AlPc–PEG and AlPc–PVA were prepared
in PBS. The final concentrations of the polymeric Pcs were deter-
mined spectroscopically 24 h after dilution in DMF to ensure
complete monomerization (e = 2.5 ´ 105 M–1 cm–1 at ~670 nm).
Solutions were kept in the dark and stored at room temperature.
Cells
Mouse mammary tumour, EMT-6 cells were maintained in
Waymouth’s medium (Gibco, Burlington, Canada) supplemented
with 15% fetal bovine serum (FBS, ICN, Aurora, Ohio) and 1%
L-glutamin (Gibco). Mouse colon adenocarcinoma, Colo-26 cells
(Tsuruo et al, 1983) were obtained from Dr B Henderson
(Rosswell Park Cancer Institute, Buffalo, NY, USA) and main-
tained in vivo by successive intradermal inoculation of thawed
cells and freezing of fresh cells prepared from homogenized
tumours.
Cellular photoinactivation
Cell survival was estimated by means of the colourimetric MTT
(3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assay (Tada et al, 1986). Briefly, 15 ´ 103 EMT-6 cells per
well were inoculated in 100 ml Waymouth’s growth medium in
96-multi-well plates and incubated overnight at 37°C and 5%
carbon dioxide. The cells were rinsed twice with PBS and incu-
bated with 100 ml of the drug at 1 mM in Waymouth’s medium
containing 1% FBS for 1 or 24 h at 37°C and 5% carbon dioxide.
After incubation, the cells were rinsed twice with PBS, refed with
100 ml Waymouth’s medium and exposed to red light. The light
source consisted of two 500 W tungsten/halogen lamps (GTE
Sylvania, Montreal, Canada) fitted with a circulating, refrigerated,
aqueous Rhodamine filter. The fluence rate calculated over the
absorbance peak of the aluminium phthalocyanine (660–700 nm)
was 10 mW cm–2 for a maximum total fluence of 36 J cm–2. The
cells were incubated at 37°C and 5% carbon dioxide overnight
before assessing cell viability. Fifty-microlitres of a fivefold
diluted MTT stock solution (Aldrich, Milwaukee, WI, USA; 5 mg
ml–1 PBS) in Waymouth’s medium were added to each well. After
3 h, 100 ml sodium dodecyl sulphate (SDS; Gibco) 10% in 0.01 N
hydrochloric acid was added in the wells. Plates were incubated
overnight at 37°C whereafter the absorbance was read at 595 nm
by means of a microplate reader (Bio-Rad, Mississauga, Ontario,
Canada). The average absorbance of the blank wells in which cells
were omitted was subtracted from the readings of the other wells.
The average absorbance of the control cells, which were incubated
with dye-free Waymouth’s 1% FBS, represents 100% cell survival.
The light dose required to inactivate 90% of the cells (LD90) was
extrapolated from the survival curves. Eightfold replicates were
run per drug and light dose and each experiment was repeated at
least three times.
Tumour models
Experiments were performed on male BALB/c mice (18–22 g)
(Charles River Breeding Laboratories, Montreal, Canada) bearing
the EMT-6 or the Colo-26 tumour following a protocol approved
by the Canadian Council on Animal Care and an in-house ethics
committee. The animals were allowed free access to water and
food throughout the course of the experiments. Before tumour
implantation, hair on the hind legs and back of the mice was
removed by shaving and chemical depilating (Nair, Whitehall,
Mississauga, Canada). One EMT-6 tumour (2–3 for the biodistrib-
ution) was implanted on each hind thigh by i.d. injection of 2 ´ 105
cells suspended in 0.05 ml growth medium. In the case of the
Colo-26 tumour, one tumour was implanted i.d. on the right hind
thigh only, by inoculation of 1 ´ 106 Colo-26 cells, to allow for a
longer follow-up of the tumour regrowth after PDT.
Biodistribution
Mice were used 10 or 11 days after cell inoculation when the
tumour diameter and thickness reached 4–8 mm and 2–4 mm
respectively. Tumour-bearing mice were injected intravenously
(i.v.) via the caudal vein with 2 mmol kg–1 of dye (0.2 ml per 20 g
body weight). At different time intervals after dye administration
(5 min to 1 week), blood was collected by intracardiac puncture by
means of a heparinized syringe, whereafter the animals (n = 4 per
time interval) were sacrificed. The blood was centrifuged in
Eppendorf tubes for 5 min at 2000 g and the plasma was collected.
One hundred microlitres of plasma or blood were mixed with
1.9 ml DMF. Organs and tissues of interest were removed, washed
with saline (0.9%) and blotted dry. Whole tumours (2–3), aliquots
of other organs and minced skin (80–150 mg) were homogenized
with a 20-fold volume of DMF using a Polytron® fitted with a
PT 10/35 rotor (Brinkmann, Mississauga, Canada). After over-
night incubation at room temperature, the homogenates were
centrifuged at 4°C (3500 rpm for 20 min). The dye concentration
in the clear supernatant was assayed by fluorescence
(Fluorescence spectrophotometer F-2000, Hitachi, Tokyo, Japan)
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tively). Calibration curves were established by adding known
amounts of dye to 100 ml plasma or blood or 80–150 mg of tissue
samples from control mice, whereafter the tissues were treated as
described above. No fluorescence was found in control tissue
samples to which no dye had been added. Plasma half-lives were
calculated by means of the Pharmkit program (version 3.00;
Johnston and Woollard R, 1990).
Photodynamic therapy
For PDT studies, mice were used 6–8 days after tumour inocula-
tion (tumour size: 3–5 mm diameter, 2–3 mm thickness). Animals
were given an i.v. injection of drugs at 0.25–10 mmol kg–1 (0.2 ml
per 20 g body weight) and the right tumour was treated with red
light 24 h later. In the case of the EMT-6 tumour, the left tumour
served as a control and animals were discarded from the analysis
when the control tumour underwent spontaneous regression or
showed abnormally slow growth. This was never observed with
Colo-26 tumour model in control animals. Tumours were illumi-
nated with a 8 mm diameter beam of 650–700 nm light
(200 mW cm–2 for a total fluence of 400 J cm–2) generated by a
1000 W Xenon lamp, equipped with a 10 cm circulating water
filter and two glass filters (Corion LL650 and LS700, Holliston,
MA, USA). A positive tumour response was assigned to tumours
that appeared macroscopically as flat and necrotic tissues within a
few days after PDT. Animals were considered cured when a
complete tumour regression, defined as the absence of a palpable
tumour, was seen at 3 weeks after PDT. In the case of the Colo-26
tumour, the percentage of cured animals was low. Therefore, the
anti-tumour activity was further evaluated in non-cured mice
through a growth-delay analysis. Tumour volume was measured
externally with a calliper according to an hemiellipsoid model [V
= 1/2 (4p/3) ´ (l/2) ´ (w/2) ´ h, l = length, w = width, h = height].
No correction was made for skin thickness. Tumour regrowth
curves were plotted for each treated tumour and the time in days
for a tumour to grow to 20 times its initial volume at the time of
phototreatment (Vo) was determined. Then, the mean (± s.e.m.)
was calculated for each treatment group (n = 6–8). In the case of
the controls, the volume of 45 untreated tumours was plotted
against the time post-inoculation and the time in days required to
reach 20 times the mean initial volume of the treated tumours
group at the time of phototreatment (Vo: 8.9 ± 0.6 mm3) was deter-
mined from the regression curve (Figure 6A). The significance of
the difference in tumour growth time between the treated and the
control group and among the treated groups was assessed by the
Student’s t-test for unpaired values.
RESULTS
Cellular photoinactivation
Photosensitization of EMT-6 cells by AlPc derivatives is shown
in Figure 3 after 1 and 24 h incubation with 1 mM dye. No dark
cytotoxicity was observed under these conditions. The light dose
required to kill 90% of cells (LD90) after 1 h incubation was
13.5 J cm–2 for AlClPc and more than 36 J cm–2 for AlPc–PEG and
AlPc–PVA. Increasing the incubation times to 24 h decreased the
LD90 to 4.5, 6 and 8.5 J cm–2 respectively.
Biodistribution studies
Plasma clearance of AlClPc and AlPc conjugates 5 and  10 is
shown in Figure 4. The half-life was 23 min, 2.6 h and 6.8 h for
AlPc–PEG (5), AlClPc and AlPc–PVA (10) respectively. A high
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Figure 3 Effect of light dose (J cm–2) on EMT-6 cell survival after 1 h (top)
and 24 h (bottom) incubation with 1 mM AlClPc (n n), AlPc–PEG (l l) and
AlPc–PVA (Ñ)
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Figure 4 Plasma clearance (mean ± sem) of AlClPc (n n), AlPc-PEG (l l) and
AlPc–PVA (Ñ) after iv injection of 2 mmol kg–1 in EMT-6 tumour bearing mice
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Figure 5 Tissue concentrations in %ID g–1 (mean ± s.e.m.) of AlClPc (n n), AIPc-PEG (l l) and AlPc-PVA (Ñ) as a function of time after i.v. injection of 2 mmol
kg–1 in EMT-6 tumour bearing mice (n = 4)
Table 1 Tumour-to-plasma and tumour-to-tissues ratios for AlClPc,
AlPc–PEG and AlPc–PVA as a function of time (h) after i.v. injection of
2 mmol kg–1 in EMT-6 tumour-bearing mice (n = 4)
6 h 24 h 48 h 168 h
AlClPc in Cremophor emulsion
Tumour-to-plasma 0.4 >> >> >>
Tumour-to-skin 3.5 5.3 3.3 2.0
Tumour-to-tumour skin 1.0 1.0 0.7 0.9
Tumour-to-muscle – 16.9 19.5 >>
AlPc-PEG in PBS
Tumour-to-plasma – >> – >>
Tumour-to-skin – 8.8 – 1.2
Tumour-to-tumour skin – 1.9 – 1.3
Tumour-to-muscle – >> – >>
AlPc-PVA in PBS
Tumour-to-plasma 0.1 1.3 21.3 >>
Tumour-to-skin – 12.5 9.8 8.2
Tumour-to-tumour skin 0.6 0.6 0.7 0.7
Tumour-to-muscle 12.6 26.9 32.3 27.0
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Figure 6 Growth of Colo-26 tumour in control mice (n = 45)1538 N Brasseur et al
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Table 2 Tumour response induced in Balb/c mice by AlPc- and PII-mediated PDT (24 h p.i., 200 m W cm–2, 400 J cm–2)
PDT treatment
Drug dose
n Voa Tumour response (% of mice) Oedemad
Regrowth to
mmol kg–1 20 Voe
(mg kg–1)m m 3 (sem) Regressionb Curec days (s.e.m.)
EMT-6 tumour
AlClPcf 0.25 8 8.7 (0.7) 100 100 + NA
AlPc–PEG 0.25 8 14.9 (1.1) 100 75 ++ NA
AlPc–PVA 0.25 8 11.9 (0.9) 100 100 +++ NA
PIIg (5) 10 NA 70 70 +++ NA
Colo-26 tumour
Controls – 45 8.9 (0.6)h – – – 15.0 (0.3)
AlClPc 2 10 10.3 (1.2) 80 30 ++ 23.5 (2.1)
AlPc–PEG 2 9 8.3 (0.5) 100 30 +++i 30.1 (1.7)
AlPc–PVA 2 9 10.3 (1.4) 90 30 +++ 32.4 (3.4)
PII (10) 8 7.9 (0.7) 100 0 +++ 24.0 (0.8)
aTumour volume at the time of PDT. bFlat and necrotic within 3–5 days after PDT. cComplete tumour regression at 14 days (EMT-6, PII) or 21 days (EMT-6, Pc)
or 30 days minimum (Colo-26) post-inoculation. dObserved 24 h after PDT, (+) light oedema, (++) oedema, (+++) extensive oedema. eTime required for a tumour
to reach 20 times the volume at the time of PDT, cured mice were excluded from this analysis. fFrom Chan et al (1997). gFrom Brasseur et al (1996). hMean
tumour volume of the 4 treated groups of non cured tumours (n = 27) was used to calculate 20 Vo in the control group (n = 45). iDamage to surrounding muscle,
limiting leg mobility and lasting for at least 35 days post-PDT was observed in 30% of mice.
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Figure 7 Growth of Colo-26 tumour in mice treated with AlClPc, AlPc-PEG and AlPc-PVA at 2 mmol kg–1 and Photofrin at 10 mg kg–1 following PDT at day 6 or
7 after tumour inoculation (n = 6–8). Cured mice were excluded from this analysisretention of the dye by the organs of the reticulo-endothelial
system, i.e. liver and spleen, was seen with all three preparations
but was much more elevated for AlClPc and AlPc–PEG
(Figure 5). Uptake by the lungs was also higher while elimination
by the kidneys was somewhat lower for AlClPc and AlPc–PEG
as compared to AlPc–PVA. Tumour uptake of AlClPc increased
gradually from 30 min to 6–24 h post-injection (pi), whereafter it
decreased. In the case of AlPc–PVA, the tumour uptake was higher
at 24 h pi and remained stable for 1-week pi. Tumour and tumour-
skin retentions of AlPc–PEG were much lower as compared to
AlClPc and AlPc–PVA. For these two dyes respectively, the skin
overlying the tumour accumulated equivalent or higher amount of
dye than the skin removed at sites away from the tumour (leg).
This correlates with high vascularization of the skin surrounding
the tumour. Retention of AlPc by normal skin and muscle was
low for all preparations. Tumour-to-tissue ratios are presented in
Table 1. The highest tumour-to-skin and tumour-to-muscle ratios
were obtained for AlPc–PVA.
Photodynamic therapy
Table 2 presents the tumour response induced by AlPc-mediated
PDT in the EMT-6 and Colo-26 tumour models implanted in Balb/c
mice. Complete EMT-6 tumour regression was achieved in 75% of
animals or more with 0.25 mmol kg–1 for all three dye preparations.
For comparison, similar tumour control was obtained with 5 mg
kg–1 Photofrin. In the Colo-26 tumour model, complete tumour
regression was found in 30% of mice with 2 mmol kg–1 for all three
dyes. However, differences were noted in the tumour growth delay
(t in days) measured in the non-cured animals (Figure 6 and 7,
Table 2). Significantly longer delays were obtained for all three dye
preparations as compared to the control tumours (P < 0.01). In
addition, AlPc–PVA (t = 32.4 ± 3.4) and AlPc-PEG (t = 30.1 ± 1.7)
gave rise to better growth delay as compared to AlClPc (t = 23.5 ±
2.1,  P = 0.04). In the case of Photofrin, no tumour cure was
observed with 10 mg kg–1 while the tumour growth delay extended
to 24 ± 0.8 days, which was different from the control (t = 15 ± 0.3,
P < 0.01) and from AlPc–PVA (P = 0.02) and AlPc–PEG (P <
0.01). Oedema was always less important with AlClPc than with
PII and the two polymeric AlPc derivatives. Impaired mobility of
the treated leg reflecting persistent damage to muscle was seen in
30% of animals, treated with AlPc–PEG at 2 mmol kg–1. In contrast,
AlClPc and AlPc–PVA at the same dose did not induce damage to
leg muscle.
DISCUSSION
Various photosensitizers have been conjugated to polymeric
carriers including chlorine to N-(2-hydroxypropyl)methacryl-
amide (Krinick et al, 1994) or to cationic, anionic or neutral poly-
L-lysine (Soukos et al, 1997). Substitution of poly-L-lysine
chlorine conjugates with PEG increases phototoxicity towards
cancer cells (Hamblin et al, 1998; Rizvi and Hasan, 1998). A tetra-
substituted PEG conjugate of the meta-(tetrahydroxyphenyl)-
chlorine (m-THPC, Foscan, Temoporfin) is under extensive study
and shows extended plasma half-life, tumour selectivity (Morlet
et al, 1997; Rheinwald et al, 1998; Rovers et al, 1998) and good
PDT efficacy (Krüger et al, 1998). Three to four methoxy-PEG
(MW 5000) linked to tetra-(4-hydroxyphenyl)-porphin (Pomer
et al, 1995) improved tumour accumulation in human renal cell
carcinoma transplanted in nude mice as compared to dihaemato-
porphyrin ether (DHE). In contrast, a water-soluble silicon-naph-
thalocyanine (SiNc) obtained by coordination of two PEG ligands
(MW 1900) in axial positions to the central metal ion (Bellemo
et al, 1992) showed poor tumour selectivity and no photothera-
peutic activity in a MS-2 fibrosarcoma transplanted in Balb/c
mice, while hydrophobic derivatives of SiNc delivered in lipo-
somes (Cuomo et al, 1990) or in Cremophor emulsion (Brasseur
et al, 1994) are good tumour photosensitizers. Modified PVA
(MW 10 000) was also loaded with benzoporphyrin derivative
(M-PVA-BPD) and tested at a molar ratio of 1:25 in the
rhabdomyosarcoma implanted in DBA/2 mice (Davis et al, 1993).
Although the level of M-PVA-BPD in tumour tissue was lower
than that of free BPD, it was shown by an in vivo/in vitro assay
that the conjugate was bound more tightly to the tumour cells and
effected higher tumour cell kill when activated by light.
We now described the conjugation of PEG and PVA to AlClPc
via an axial coordination bond. The photodynamic potential of the
polymeric AlPc conjugates was first evaluated at the cellular level.
The AlClPc emulsion was more phototoxic than AlPc–PEG and
AlPc–PVA after 1 h incubation, reflecting its faster rate of cellular
uptake. However, after 24 h incubation, differences in photo-
activity among the three dye preparations were much less
pronounced. AlClPc photoactivity is consistent with literature data
(Ben-Hur and Rosenthal, 1986; Chan et al, 1987; Daziano et al,
1996; Rasch et al, 1996). However, among the phthalocyanines
evaluated in our laboratory, these AlPc derivatives are not the most
active on cell cultures. The monosulphododecafluoro zinc Pc
derivative, ZnPcF12 S1, for example, was much more active (LD90
24 h inc.: 0.25 J cm–2) but this substantial cellular photoinactiva-
tion correlated with high level of mortality after PDT in mice
(Allémann et al, 1997). In contrast, in terms of drug dosage
required for efficient in vivo PDT, AlClPc and its two polymeric
conjugates are among the most active phthalocyanines tested to
date in our laboratory (Larroque et al, 1996; Chan et al, 1997;
Hu et al, 1998). This again confirms that the level of in vitro
photoinactivation is not predictive for in vivo photoefficacy.
Biodistribution studies performed in EMT-6 tumour-bearing
mice revealed important differences among the three dyes in the
rate of plasmatic clearance as well as in the level of tissue uptake.
It is evident that the delivery vehicle and the polymeric moiety
affects the tissue distribution of AlPc substantially. It is well
known that Cremophor increases the plasma circulation time of a
drug by altering plasma lipoproteins and promotes its distribution
to neoplastic tissues (Woodburn et al, 1994), as also observed for
the Cremophor emulsion of AlClPc (t1/2 2.6 h). However, impor-
tant and persistent retention of AlClPc by the liver (73% at 1-week
pi) could result in hepatic toxicity. In contrast, AlPc-PEG was
cleared readily from the circulation (t1/2 23 min), while the dye
retention by the reticulo-endothelial system was rapid and elevated
resulting in a very low tumour uptake. These data are in agreement
with a study on the effect of the molecular weight (MW) of the PEG
on its half-life in circulation and its body distribution (Yamaoka et
al, 1994). Small PEG polymers, such as used in our study (MW
2000), tend to freely translocate from the circulation to extravascular
tissues, whereas large PEGs translocate more slowly. The plasma
half-life increases from 18 min to 1 day with increasing PEG MW
from 6000 to 190 000, whereas liver clearance increases with the
increasing PEG MW. The most interesting pharmacokinetic profile
was obtained with AlPc–PVA, which showed the longest plasma
circulation time (t1/2 6.8 h). This effect on the rate of plasmatic
clearance could relate to the higher MW of the polymer
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increased hydrophilicity when compared to AlClPc. AlPc–PVA also
exhibited the lowest retention by the liver, spleen and lungs, the best
tumour-to-skin and tumour-to-muscle ratios (12 and 27 respectively
at 24 h pi) as well as the highest and most persistent tumour uptake,
which allows for repeated PDT treatments.
PDT of the EMT-6 tumour showed that water-soluble AlPc
conjugates were able to induce substantial tumour control at the
same low drug dose (0.25 mmol kg–1) as unsubstituted AlClPc.
Due to the well-known immunogenicity of the EMT-6 tumour
(Henderson et al, 1985), the photodynamic potential of the conju-
gates was further evaluated on the Colo-26 tumour model. The
absence of immunogenicity of the latter tumour may explain, at
least in part, the lower level of tumour regression (30% of mice)
obtained at higher drug dose (2 mmol kg–1). However, significantly
longer tumour regrowth delays were observed in the non-cured
treated mice as compared to untreated animals. A two-time
increase was observed in the case of AlPc–PVA and AlPc–PEG,
while in the case of AlClPc and PII (10 mg kg–1) the growth delay
was only 1.5 times that of the controls. Surprisingly, despite very
low tumour uptake as compared to AlClPc and AlPc–PVA,
AlPc–PEG was able to induce a similar tumour control rate. Also,
plasma levels of AlPc–PEG at the time of phototreatment were
below the detection limit. This suggests that the residual amount of
dye present in the tumour is distributed to sites of higher photo-
dynamic sensitivity. While the photodynamic potential of AlClPc
was maintained or even increased by addition of a PEG or PVA
molecule, the low extent of oedema induced with the unsubstituted
AlClPc was lost. This does not seem to be related to differential
dye retention by the muscle or skin, since the uptake by these
tissues is very similar and quite low for all three dye preparations.
However, more important damages to the muscle surrounding the
tumour were observed with AlPc–PEG as compared to AlPc–PVA.
In conclusion, we have shown that the water-soluble AlPc–PVA
and AlPc–PEG conjugates exhibit photodynamic activities similar
or superior to that of the unsubstituted AlClPc. The relatively low
drug dosage required to induce tumour control in the two different
models suggests that these conjugates are among the most active
water-soluble photosensitizers currently under evaluation. Finally,
AlPc–PVA has the advantage of lower splenic and hepatic reten-
tions and less incidence of damage to normal tissues as compared
to AlPc–PEG.
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